Effect of hypoglycemia on brain structure in people with type 2 diabetes: epidemiological analysis of the ACCORD-MIND MRI trial

Zi Zhang, James Lovato, Harsha Battapady, Christos Davatzikos, Hertzel C Gerstein, Faramarz Ismail-Beigi, Lenore J Launer, Anne Murray, Zubin Punthakee, Amilcar A Tirado, Jeff Williamson, R Nick Bryan, Michael E Miller, Zi Zhang, James Lovato, Harsha Battapady, Christos Davatzikos, Hertzel C Gerstein, Faramarz Ismail-Beigi, Lenore J Launer, Anne Murray, Zubin Punthakee, Amilcar A Tirado, Jeff Williamson, R Nick Bryan, Michael E Miller

Abstract

Objective: The effect of hypoglycemia related to treatment of type 2 diabetes mellitus (T2DM) on brain structure remains unclear. We aimed to assess whether symptomatic severe hypoglycemia is associated with brain atrophy and/or white matter abnormalities.

Research design and methods: We included T2DM participants with brain MRI from the Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) trial. Symptomatic severe hypoglycemia was defined as blood glucose <2.8 mmol/L or symptoms resolved with treatments that required the assistance of another person or medical assistance (hypoglycemia requiring assistance [HA]). Standardized brain MRI was performed at baseline and at 40 months. Total brain volume (TBV) and abnormal white matter (AWM) volume were calculated using an automated computer algorithm. Brain MRI scans of hypoglycemic participants were also reviewed for local disease.

Results: Of the 503 T2DM participants (mean age, 62 years) with successful baseline and 40-month brain MRI, 28 had at least one HA episode during the 40-month follow-up. Compared with participants without HA, those with HA had marginally significant less atrophy (less decrease in TBV) from baseline to 40 months (-9.55 [95% CI -15.21, -3.90] vs. -15.38 [95% CI -16.64, -14.12], P = 0.051), and no significant increase of AWM volume (2.06 [95% CI 1.71, 2.49] vs. 1.84 [95% CI 1.76, 1.91], P = 0.247). In addition, no unexpected local signal changes or volume loss were seen on hypoglycemic participants' brain MRI scans.

Conclusions: Our study suggests that hypoglycemia related to T2DM treatment may not accentuate brain pathology, specifically brain atrophy or white matter abnormalities.

Trial registration: ClinicalTrials.gov NCT00182910.

© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

References

    1. Seaquist ER, Anderson J, Childs B, et al. . Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013;36:1384–1395
    1. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP, Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009;301:1565–1572
    1. Jacobson AM, Musen G, Ryan CM, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group . Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007;356:1842–1852
    1. Draelos MT, Jacobson AM, Weinger K, et al. . Cognitive function in patients with insulin-dependent diabetes mellitus during hyperglycemia and hypoglycemia. Am J Med 1995;98:135–144
    1. Warren RE, Frier BM. Hypoglycaemia and cognitive function. Diabetes Obes Metab 2005;7:493–503
    1. Kaufman FR, Epport K, Engilman R, Halvorson M. Neurocognitive functioning in children diagnosed with diabetes before age 10 years. J Diabetes Complications 1999;13:31–38
    1. Wredling R, Levander S, Adamson U, Lins PE. Permanent neuropsychological impairment after recurrent episodes of severe hypoglycaemia in man. Diabetologia 1990;33:152–157
    1. Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies. Diabetologia 2005;48:2460–2469
    1. van de Ven KC, Tack CJ, Heerschap A, van der Graaf M, de Galan BE. Patients with type 1 diabetes exhibit altered cerebral metabolism during hypoglycemia. J Clin Invest 2013;123:623–629
    1. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304–309
    1. Seaquist ER, Lattemann DF, Dixon RA. American Diabetes Association research symposium: diabetes and the brain. Diabetes 2012;61:3056–3062
    1. Frisoni GB, Fox NC, Jack CR, Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010;6:67–77
    1. Driscoll I, Davatzikos C, An Y, et al. . Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. Neurology 2009;72:1906–1913
    1. Fox NC, Scahill RI, Crum WR, Rossor MN. Correlation between rates of brain atrophy and cognitive decline in AD. Neurology 1999;52:1687–1689
    1. Sluimer JD, van der Flier WM, Karas GB, et al. . Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. Radiology 2008;248:590–598
    1. Schott JM, Crutch SJ, Frost C, Warrington EK, Rossor MN, Fox NC. Neuropsychological correlates of whole brain atrophy in Alzheimer’s disease. Neuropsychologia 2008;46:1732–1737
    1. van Harten B, de Leeuw FE, Weinstein HC, Scheltens P, Biessels GJ. Brain imaging in patients with diabetes: a systematic review. Diabetes Care 2006;29:2539–2548
    1. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010;341:c3666.
    1. Williamson JD, Miller ME, Bryan RN, et al. ACCORD Study Group . The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. Am J Cardiol 2007;99:112i–122i
    1. Sawyer-Glover AM, Shellock FG. Pre-MRI procedure screening: recommendations and safety considerations for biomedical implants and devices. J Magn Reson Imaging 2000;12:92–106
    1. Bonds DE, Kurashige EM, Bergenstal R, et al. ACCORD Study Group . Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:80i–89i
    1. Bonds DE, Miller ME, Bergenstal RM, et al. . The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909.
    1. Launer LJ, Miller ME, Williamson JD, et al. ACCORD MIND investigators . Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol 2011;10:969–977
    1. Goldszal AF, Davatzikos C, Pham DL, Yan MX, Bryan RN, Resnick SM. An image-processing system for qualitative and quantitative volumetric analysis of brain images. J Comput Assist Tomogr 1998;22:827–837
    1. Lao Z, Shen D, Liu D, et al. . Computer-assisted segmentation of white matter lesions in 3D MR images using support vector machine. Acad Radiol 2008;15:300–313
    1. Cryer P. Hypoglycemia in Diabetes: Pathophysiology, Prevalence, and Prevention. Alexandria, VA, American Diabetes Association, 2009
    1. Cryer PE. Hypoglycemia, functional brain failure, and brain death. J Clin Invest 2007;117:868–870
    1. Böttcher J, Kunze A, Kurrat C, et al. . Localized reversible reduction of apparent diffusion coefficient in transient hypoglycemia-induced hemiparesis. Stroke 2005;36:e20–e22
    1. Aoki T, Sato T, Hasegawa K, Ishizaki R, Saiki M. Reversible hyperintensity lesion on diffusion-weighted MRI in hypoglycemic coma. Neurology 2004;63:392–393
    1. Chan R, Erbay S, Oljeski S, Thaler D, Bhadelia R. Case report: hypoglycemia and diffusion-weighted imaging. J Comput Assist Tomogr 2003;27:420–423
    1. Maruya J, Endoh H, Watanabe H, Motoyama H, Abe H. Rapid improvement of diffusion-weighted imaging abnormalities after glucose infusion in hypoglycaemic coma. BMJ Case Rep 2009;2009
    1. Hasegawa Y, Formato JE, Latour LL, et al. . Severe transient hypoglycemia causes reversible change in the apparent diffusion coefficient of water. Stroke 1996;27:1648–1655; discussion 1655–1656
    1. Kim JH, Roh JH, Koh SB. Reversible injury of internal capsule and splenium in a patient with transient hypoglycemic hemiparesis. Cerebrovasc Dis 2006;22:282–283
    1. Gallucci M, Limbucci N, Paonessa A, Caranci F. Reversible focal splenial lesions. Neuroradiology 2007;49:541–544
    1. Albayram S, Ozer H, Gokdemir S, et al. . Reversible reduction of apparent diffusion coefficient values in bilateral internal capsules in transient hypoglycemia-induced hemiparesis. AJNR Am J Neuroradiol 2006;27:1760–1762
    1. Maekawa S, Aibiki M, Kikuchi K, Kikuchi S, Umakoshi K. Time related changes in reversible MRI findings after prolonged hypoglycemia. Clin Neurol Neurosurg 2006;108:511–513
    1. Lo L, Tan AC, Umapathi T, Lim CC. Diffusion-weighted MR imaging in early diagnosis and prognosis of hypoglycemia. AJNR Am J Neuroradiol 2006;27:1222–1224
    1. Kang EG, Jeon SJ, Choi SS, Song CJ, Yu IK. Diffusion MR imaging of hypoglycemic encephalopathy. AJNR Am J Neuroradiol 2010;31:559–564
    1. UK Hypoglycaemia Study Group . Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140–1147
    1. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169–3176
    1. Akram K, Pedersen-Bjergaard U, Carstensen B, Borch-Johnsen K, Thorsteinsson B. Frequency and risk factors of severe hypoglycaemia in insulin-treated type 2 diabetes: a cross-sectional survey. Diabet Med 2006;23:750–756
    1. Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–2559

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다